Up to 44 percent of papillary thyroid cancer patients have a B - raf mutation that can be specifically targeted by existing cancer drugs. (sciencedaily.com)
«Targeted therapies show initial effectiveness in subset of papillary thyroid cancer.» (sciencedaily.com)
The lesions evaluated in this study that can become cancerous are known as intraductal papillary mucinous neoplasms. (sciencedaily.com)